Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Sarcoma 1Neoplasm Metastasis 1Hematologic Neoplasms 1

Interventions

venetoclax 190Azacitidine 162Cytarabine 127fludarabine 97Cyclophosphamide 75Specimen Handling 68fludarabine phosphate 56Daunorubicin 53Biopsy 49Decitabine 48Whole-Body Irradiation 42Mycophenolic Acid 40Idarubicin 40Busulfan 37Injections 36Tacrolimus 35Granulocyte Colony-Stimulating Factor 35Melphalan 32Stem Cell Transplantation 30gilteritinib 25Filgrastim 25CPX-351 25decitabine and cedazuridine drug combination 23Peripheral Blood Stem Cell Transplantation 22Etoposide 20ivosidenib 19Mitoxantrone 19Cladribine 19Thiotepa 17Sirolimus 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × siremadlin × 1 year × Clear all
NCT05155709 2026-05-07

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Novartis

Phase 1 Completed
14 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03940352 2025-10-10

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Novartis

Phase 1 Terminated
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡